Patents Assigned to REVAGENIX, INC.
  • Modular synthesis of aminoglycosides
    Patent number: 12129274
    Abstract: The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: October 29, 2024
    Assignee: Revagenix, Inc.
    Inventors: Andrew Antony Calabrese, Timothy Robert Kane, Darin Hildebrandt, Michael Lopez, Nikolai Evdokimov, Frederick Cohen, Malken Bayrakdarian, Sanijia Xu, Samuel Desjardins, Olivier Soueidan
  • Modular synthesis of aminoglycosides
    Patent number: 11673907
    Abstract: The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: June 13, 2023
    Assignee: Revagenix, Inc.
    Inventors: Andrew Calabrese, Timothy Robert Kane, Darin Hildebrandt, Michael Lopez, Nikolai Evdokimov, Frederick Cohen, Malken Bayrakdarian, Sanjia Xu, Samuel Desjardins, Olivier Soueidan
  • MODULAR SYNTHESIS OF AMINOGLYCOSIDES
    Publication number: 20220411456
    Abstract: The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.
    Type: Application
    Filed: August 24, 2018
    Publication date: December 29, 2022
    Applicant: Revagenix, Inc.
    Inventors: Andrew CALABRESE, Timothy Robort KANE, Darin HILDEBRANDT, Michael LOPEZ, Nikolai EVDOKIMOV, Frederick COHEN, Malken BAYRAKDARIAN, Sanijia XU, Samuel DESJARDINS, Olivier SOUEIDAN
  • Aminoglycosides and uses thereof
    Patent number: 11414450
    Abstract: Provided herein are aminoglycoside compounds, such as compounds of formula (I), (II), (III), (IV), (IVa), (V), (VI), (VIIa), or (VIIb) or pharmaceutically acceptable salts, solvates, stereoisomers, or tautomers of any of the foregoing, useful as therapeutic or prophylactic agents. Also provided herein are methods for their preparation. The compounds may be useful in treating a bacterial infection in a subject, for example a Gram-negative bacterial infection.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: August 16, 2022
    Assignee: REVAGENIX, INC.
    Inventors: Logan Andrews, Andrew Calabrese, Timothy Robert Kane, Ryan Cirz, Frederick Cohen, Michael Lopez, John Knox, Nikolai Evdokimov